EMBO Molecular Medicine (Sep 2018)
Comparative proteomics reveals a diagnostic signature for pulmonary head‐and‐neck cancer metastasis
- Hanibal Bohnenberger,
- Lars Kaderali,
- Philipp Ströbel,
- Diego Yepes,
- Uwe Plessmann,
- Neekesh V Dharia,
- Sha Yao,
- Carina Heydt,
- Sabine Merkelbach‐Bruse,
- Alexander Emmert,
- Jonatan Hoffmann,
- Julius Bodemeyer,
- Kirsten Reuter‐Jessen,
- Anna‐Maria Lois,
- Leif Hendrik Dröge,
- Philipp Baumeister,
- Christoph Walz,
- Lorenz Biggemann,
- Roland Walter,
- Björn Häupl,
- Federico Comoglio,
- Kuan‐Ting Pan,
- Sebastian Scheich,
- Christof Lenz,
- Stefan Küffer,
- Felix Bremmer,
- Julia Kitz,
- Maren Sitte,
- Tim Beißbarth,
- Marc Hinterthaner,
- Martin Sebastian,
- Joachim Lotz,
- Hans‐Ulrich Schildhaus,
- Hendrik Wolff,
- Bernhard C Danner,
- Christian Brandts,
- Reinhard Büttner,
- Martin Canis,
- Kimberly Stegmaier,
- Hubert Serve,
- Henning Urlaub,
- Thomas Oellerich
Affiliations
- Hanibal Bohnenberger
- Institute of Pathology University Medical Center Göttingen Germany
- Lars Kaderali
- Institute of Bioinformatics University Medicine Greifswald Greifswald Germany
- Philipp Ströbel
- Institute of Pathology University Medical Center Göttingen Germany
- Diego Yepes
- Department of Medicine II Hematology/Oncology Goethe University Frankfurt Germany
- Uwe Plessmann
- Bioanalytical Mass Spectrometry Group Max Planck Institute for Biophysical Chemistry Göttingen Germany
- Neekesh V Dharia
- Department of Pediatric Oncology Dana‐Farber Cancer Institute Boston MA USA
- Sha Yao
- Institute of Pathology University Medical Center Göttingen Germany
- Carina Heydt
- Institute of Pathology University Hospital Cologne University of Cologne Köln Germany
- Sabine Merkelbach‐Bruse
- Institute of Pathology University Hospital Cologne University of Cologne Köln Germany
- Alexander Emmert
- Department of Thoracic and Cardiovascular Surgery University Medical Center Göttingen Germany
- Jonatan Hoffmann
- Institute of Pathology University Medical Center Göttingen Germany
- Julius Bodemeyer
- Institute of Pathology University Medical Center Göttingen Germany
- Kirsten Reuter‐Jessen
- Institute of Pathology University Medical Center Göttingen Germany
- Anna‐Maria Lois
- Institute of Pathology University Medical Center Göttingen Germany
- Leif Hendrik Dröge
- Department of Radiooncology University Medical Center Göttingen Germany
- Philipp Baumeister
- Department of Otorhinolaryngology University Hospital Munich Ludwig‐Maximilian‐University München München Germany
- Christoph Walz
- Institute of Pathology Faculty of Medicine LMU Munich Munich Germany
- Lorenz Biggemann
- Institute for Diagnostic and Interventional Radiology University Medical Center Göttingen Germany
- Roland Walter
- Department of Medicine II Hematology/Oncology Goethe University Frankfurt Germany
- Björn Häupl
- Department of Medicine II Hematology/Oncology Goethe University Frankfurt Germany
- Federico Comoglio
- Department of Haematology University of Cambridge Cambridge UK
- Kuan‐Ting Pan
- Bioanalytical Mass Spectrometry Group Max Planck Institute for Biophysical Chemistry Göttingen Germany
- Sebastian Scheich
- Department of Medicine II Hematology/Oncology Goethe University Frankfurt Germany
- Christof Lenz
- Bioanalytical Mass Spectrometry Group Max Planck Institute for Biophysical Chemistry Göttingen Germany
- Stefan Küffer
- Institute of Pathology University Medical Center Göttingen Germany
- Felix Bremmer
- Institute of Pathology University Medical Center Göttingen Germany
- Julia Kitz
- Institute of Pathology University Medical Center Göttingen Germany
- Maren Sitte
- Institute of Medical Statistics University Medical Center Göttingen Germany
- Tim Beißbarth
- Institute of Medical Statistics University Medical Center Göttingen Germany
- Marc Hinterthaner
- Department of Thoracic and Cardiovascular Surgery University Medical Center Göttingen Germany
- Martin Sebastian
- Department of Medicine II Hematology/Oncology Goethe University Frankfurt Germany
- Joachim Lotz
- Institute for Diagnostic and Interventional Radiology University Medical Center Göttingen Germany
- Hans‐Ulrich Schildhaus
- Institute of Pathology University Medical Center Göttingen Germany
- Hendrik Wolff
- University Medical Center Göttingen Germany
- Bernhard C Danner
- Department of Thoracic and Cardiovascular Surgery University Medical Center Göttingen Germany
- Christian Brandts
- Department of Medicine II Hematology/Oncology Goethe University Frankfurt Germany
- Reinhard Büttner
- Institute of Pathology University Hospital Cologne University of Cologne Köln Germany
- Martin Canis
- Department of Otorhinolaryngology University Hospital Munich Ludwig‐Maximilian‐University München München Germany
- Kimberly Stegmaier
- Department of Pediatric Oncology Dana‐Farber Cancer Institute Boston MA USA
- Hubert Serve
- Department of Medicine II Hematology/Oncology Goethe University Frankfurt Germany
- Henning Urlaub
- Bioanalytical Mass Spectrometry Group Max Planck Institute for Biophysical Chemistry Göttingen Germany
- Thomas Oellerich
- Department of Medicine II Hematology/Oncology Goethe University Frankfurt Germany
- DOI
- https://doi.org/10.15252/emmm.201708428
- Journal volume & issue
-
Vol. 10,
no. 9
pp. n/a – n/a
Abstract
Abstract Patients with head‐and‐neck cancer can develop both lung metastasis and primary lung cancer during the course of their disease. Despite the clinical importance of discrimination, reliable diagnostic biomarkers are still lacking. Here, we have characterised a cohort of squamous cell lung (SQCLC) and head‐and‐neck (HNSCC) carcinomas by quantitative proteomics. In a training cohort, we quantified 4,957 proteins in 44 SQCLC and 30 HNSCC tumours. A total of 518 proteins were found to be differentially expressed between SQCLC and HNSCC, and some of these were identified as genetic dependencies in either of the two tumour types. Using supervised machine learning, we inferred a proteomic signature for the classification of squamous cell carcinomas as either SQCLC or HNSCC, with diagnostic accuracies of 90.5% and 86.8% in cross‐ and independent validations, respectively. Furthermore, application of this signature to a cohort of pulmonary squamous cell carcinomas of unknown origin leads to a significant prognostic separation. This study not only provides a diagnostic proteomic signature for classification of secondary lung tumours in HNSCC patients, but also represents a proteomic resource for HNSCC and SQCLC.
Keywords